ketendoКлиническая и экспериментальная тиреоидологияClinical and experimental thyroidology1995-54722310-3787Endocrinology Research Centre10.14341/ket12786ketendo-12786Research ArticleНАУЧНЫЙ ОБЗОРREVIEWПотенциальные белковые маркеры для дифференциальной диагностики новообразований щитовидной железыPotential protein markers for differential diagnosis of thyroid neoplasmshttps://orcid.org/0009-0000-2208-0986АксеноваТ. Н.AksenovaT. N.

Аксенова Татьяна Николаевна - врач-эндокринолог, аспирант.

117292, Москва, ул. Дм. Ульянова, д. 11

Tatyana N. Aksenova - postgraduate student.

11 Dmitriya Ulyanova street, 117292, Moscow

tanya.ak.1997@mail.ruhttps://orcid.org/0000-0003-2122-2297БондаренкоЕ. В.BondarenkoE. V.

Бондаренко Екатерина Владимировна - к.м.н., руководитель Центра биобанкирования.

Москва

Ekaterina V. Bondarenko - MD, PhD.

Moscow

bondarenko.ekaterina@endocrincentr.ruhttps://orcid.org/0000-0001-9002-1662ИоутсиВ. А.IoutsiV. A.

Иоутси Виталий Алексеевич - к.х.н., заведующий лабораторией метаболомных и протеомных исследований.

Москва

Vitaliy A. Ioutsi - PhD.

Moscow

ioutsi.vitalij@endocrincentr.ruhttps://orcid.org/0000-0001-8580-2421АбдулхабироваФ. М.AbdulkhabirovaF. M.

Абдулхабирова Фатима Магомедовна - к.м.н., заведующая лабораторией цитологии и цитогенетики отдела фундаментальной патоморфологии.

Москва

Fatima M. Abdulhabirova - MD, PhD.

Moscow

Abdulkhabirova@endocrincentr.ruhttps://orcid.org/0000-0001-6338-7490ВанушкоВ. Э.VanushkoV. E.

Ванушко Владимир Эдуардович - д.м.н., заведующий хирургическим отделением №2.

Москва

Vladimir E. Vanushko - MD, PhD.

Moscow

Vanushko.Vladimir@endocrincentr.ruhttps://orcid.org/0000-0002-8216-517XБелоусовП. В.BelousovP. V.

Белоусов Павел Владимирович - старший научный сотрудник лаборатории онкоэндокринологии.

Москва

Pavel V. Belousov.

Moscow

belousov.pavel@endocrincentr.ruДзодзаеваА. В.DzodzaevaA. V.

Дзодзаева Ария Валерьевна - врач-эндокринолог.

Москва

Aria V. Dzodzaeva - MD.

Moscow

Dzodzaeva.Ariya@endocrincentr.ruhttps://orcid.org/0000-0001-9464-4402КициловскаяН. А.KitsilovskayaN. A.

Кициловская Наталья Алексеевна.

Москва

Natalia A. Kitsilovskaya.

Moscow

n.kitsilovskaya@sysbiomed.ruhttps://orcid.org/0000-0002-9717-9742МокрышеваН. Г.MokryshevaN. G.

Мокрышева Наталья Георгиевна - д.м.н., профессор, член-корреспондент Российской академии наук.

Москва

Natalia G. Mokrysheva - MD, PhD, Professor.

Moscow

mokrisheva.natalia@endocrincentr.ruНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian Federation2024100620242015667Copyright © Аксенова Т.Н., Бондаренко Е.В., Иоутси В.А., Абдулхабирова Ф.М., Ванушко В.Э., Белоусов П.В., Дзодзаева А.В., Кициловская Н.А., Мокрышева Н.Г., 20242024Аксенова Т.Н., Бондаренко Е.В., Иоутси В.А., Абдулхабирова Ф.М., Ванушко В.Э., Белоусов П.В., Дзодзаева А.В., Кициловская Н.А., Мокрышева Н.Г.Aksenova T.N., Bondarenko E.V., Ioutsi V.A., Abdulkhabirova F.M., Vanushko V.E., Belousov P.V., Dzodzaeva A.V., Kitsilovskaya N.A., Mokrysheva N.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.cet-endojournals.ru/jour/article/view/12786

Опухоли щитовидной железы (ЩЖ) чрезвычайно распространены. Заболеваемость злокачественными новообразованиями ЩЖ быстро возросла за последние десятилетия, хотя неясно, является ли это истинным увеличением или результатом широкого использования скринингового ультразвукового исследования. Стандартизированной диагностической манипуляцией, определяющей риск злокачественного потенциала и показания для оперативного лечения образований ЩЖ, является тонкоигольная аспирационная биопсия (ТАБ) с последующим цитологическим исследованием клеточного аспирата. Несмотря на то, что в превалирующем проценте случаев удается провести дифференциальную диагностику между раком щитовидной железы (РЩЖ) и доброкачественным образованиями ЩЖ, существует проблема диагностики при промежуточных категориях цитологических заключений по Bethesda, что обусловливает необходимость поиска альтернативных решений. Это определяет потребность в расширении предоперационных диагностических возможностях. Одним из ключевых направлений работы по ее реализации является изучение протеомных данных при различных патологиях ЩЖ. Изучение протеома опухолей ЩЖ открывает возможность выявления специфических белковых маркеров или механизмов, которые играют ключевую роль в онкогенезе, метастазировании опухолей ЩЖ, а также определения потенциальных мишеней для новых методов диагностики и лечения этих заболеваний. Все вышеизложенное определяет актуальность и практическую значимость изучения патологии ЩЖ на молекулярном уровне, рассмотрения потенциала белков как маркеров.

Tumors of the thyroid gland are extremely common. The incidence of malignant thyroid neoplasms has increased rapidly in recent decades, although it is unclear whether this is a true increase or the result of widespread use of screening ultrasound. The standard diagnostic procedure for determining the risk of malignancy and indications for surgical treatment of thyroid neoplasms is fine-needle aspiration biopsy followed by cytologic examination of the cellular aspirate. Despite the fact that in the majority of cases it is possible to make a differential diagnosis between thyroid cancer and benign thyroid masses, there is a diagnostic problem with intermediate categories of cytologic findings according to Bethesda, which makes it necessary to search for alternative solutions. This determines the need to expand preoperative diagnostic possibilities. One of the key directions of work on its realization is the study of proteomic data in various thyroid pathologies. The study of the proteome of thyroid tumors opens the possibility of identifying specific protein markers or mechanisms that play a key role in the oncogenesis and metastasis of thyroid tumors, as well as potential targets for new methods of diagnosis and treatment of these diseases. All this determines the relevance and practical importance of studying thyroid pathology at the molecular level, taking into account the potential of proteins as markers.

белковые маркерырак щитовидной железыаденома щитовидной железыдиагностикапротеомикаprotein markersthyroid cancerthyroid adenomadiagnosisproteomicsРабота выполнена при финансировании гранта Минобрнауки, соглашение 075–15–2022–310 от 20.04.2022.ReferencesSiegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi: https://doi.org/10.3322/caac.21763Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi: https://doi.org/10.3322/caac.21763Pizzato M, Li M, Vignat J, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022;10(4):264-272. doi: https://doi.org/10.1016/S2213-8587(22)00035-3Pizzato M, Li M, Vignat J, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022;10(4):264-272. doi: https://doi.org/10.1016/S2213-8587(22)00035-3Li M, Maso LD, Vaccarella S. Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 2020;8(6):468-470. doi: https://doi.org/10.1016/S2213-8587(20)30115-7Li M, Maso LD, Vaccarella S. Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 2020;8(6):468-470. doi: https://doi.org/10.1016/S2213-8587(20)30115-7Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol. 2020;16(1):17-29. doi: https://doi.org/10.1038/s41574-019-0263-xKim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol. 2020;16(1):17-29. doi: https://doi.org/10.1038/s41574-019-0263-xUppal N, Collins R, James B. Thyroid nodules: Global, economic, and personal burdens. Front Endocrinol (Lausanne). 2023;14. doi: https://doi.org/10.3389/fendo.2023.1113977Uppal N, Collins R, James B. Thyroid nodules: Global, economic, and personal burdens. Front Endocrinol (Lausanne). 2023;14. doi: https://doi.org/10.3389/fendo.2023.1113977Alexander EK, Cibas ES. Diagnosis of thyroid nodules. Lancet Diabetes Endocrinol. 2022;10(7):533-539. doi: https://doi.org/10.1016/S2213-8587(22)00101-2Alexander EK, Cibas ES. Diagnosis of thyroid nodules. Lancet Diabetes Endocrinol. 2022;10(7):533-539. doi: https://doi.org/10.1016/S2213-8587(22)00101-2Horvath E, Majlis S, Rossi R, et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab. 2009. doi: https://doi.org/10.1210/jc.2008-1724Horvath E, Majlis S, Rossi R, et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab. 2009. doi: https://doi.org/10.1210/jc.2008-1724Russ G, Bonnema SJ, Erdogan MF, Durante C, Ngu R, Leenhardt L. European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS. Eur Thyroid J. 2017;6(5):225-237. doi: https://doi.org/10.1159/000478927Russ G, Bonnema SJ, Erdogan MF, Durante C, Ngu R, Leenhardt L. European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS. Eur Thyroid J. 2017;6(5):225-237. doi: https://doi.org/10.1159/000478927Trimboli P, Ngu R, Royer B, et al. A multicentre validation study for the EU‐TIRADS using histological diagnosis as a gold standard. Clin Endocrinol (Oxf). 2019;91(2):340-347. doi: https://doi.org/10.1111/cen.13997Trimboli P, Ngu R, Royer B, et al. A multicentre validation study for the EU‐TIRADS using histological diagnosis as a gold standard. Clin Endocrinol (Oxf). 2019;91(2):340-347. doi: https://doi.org/10.1111/cen.13997Ali SZ, Baloch ZW, Cochand-Priollet B, Schmitt FC, Vielh P, VanderLaan PA. The 2023 Bethesda System for Reporting Thyroid Cytopathology. Thyroid®. July 2023. doi: https://doi.org/10.1089/thy.2023.0141Ali SZ, Baloch ZW, Cochand-Priollet B, Schmitt FC, Vielh P, VanderLaan PA. The 2023 Bethesda System for Reporting Thyroid Cytopathology. Thyroid®. July 2023. doi: https://doi.org/10.1089/thy.2023.0141Medina Chamorro FM, Calle JA, Stein JE, Merchancano L, Mendoza Briñez AM, Pulido Wilches AA. Experience of the Implementation of Rapid On-Site Evaluation in Ultrasound-Guided Fine-Needle Aspiration Biopsy of Thyroid Nodules. Curr Probl Diagn Radiol. 2018;47(4):220-224. doi: https://doi.org/10.1067/j.cpradiol.2017.06.009Medina Chamorro FM, Calle JA, Stein JE, Merchancano L, Mendoza Briñez AM, Pulido Wilches AA. Experience of the Implementation of Rapid On-Site Evaluation in Ultrasound-Guided Fine-Needle Aspiration Biopsy of Thyroid Nodules. Curr Probl Diagn Radiol. 2018;47(4):220-224. doi: https://doi.org/10.1067/j.cpradiol.2017.06.009Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. doi: https://doi.org/10.1089/thy.2015.0020Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. doi: https://doi.org/10.1089/thy.2015.0020Yaprak Bayrak B, Eruyar AT. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology. BMC Endocr Disord. 2020;20(1):48. doi: https://doi.org/10.1186/s12902-020-0530-9Yaprak Bayrak B, Eruyar AT. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology. BMC Endocr Disord. 2020;20(1):48. doi: https://doi.org/10.1186/s12902-020-0530-9Ban Y, Yamamoto G, Takada M, et al. Proteomic Profiling of Thyroid Papillary Carcinoma. J Thyroid Res. 2012;2012:1-7. doi: https://doi.org/10.1155/2012/815079Ban Y, Yamamoto G, Takada M, et al. Proteomic Profiling of Thyroid Papillary Carcinoma. J Thyroid Res. 2012;2012:1-7. doi: https://doi.org/10.1155/2012/815079Wei X, Zhang Y, Yu S, et al. PDLIM5 identified by label-free quantitative proteomics as a potential novel biomarker of papillary thyroid carcinoma. Biochem Biophys Res Commun. 2018;499(2):338-344. doi: https://doi.org/10.1016/j.bbrc.2018.03.159Wei X, Zhang Y, Yu S, et al. PDLIM5 identified by label-free quantitative proteomics as a potential novel biomarker of papillary thyroid carcinoma. Biochem Biophys Res Commun. 2018;499(2):338-344. doi: https://doi.org/10.1016/j.bbrc.2018.03.159Farrokhi Yekta R, Arefi Oskouie A, Rezaei Tavirani M, Mohajeri-Tehrani MR, Soroush AR. Decreased apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid carcinoma: A proteomic study. Int J Biol Markers. 2018;33(4):455-462. doi: https://doi.org/10.1177/1724600818787752Farrokhi Yekta R, Arefi Oskouie A, Rezaei Tavirani M, Mohajeri-Tehrani MR, Soroush AR. Decreased apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid carcinoma: A proteomic study. Int J Biol Markers. 2018;33(4):455-462. doi: https://doi.org/10.1177/1724600818787752Sofiadis A, Becker S, Hellman U, et al. Proteomic profiling of follicular and papillary thyroid tumors. Eur J Endocrinol. 2012;166(4):657-667. doi: https://doi.org/10.1530/EJE-11-0856Sofiadis A, Becker S, Hellman U, et al. Proteomic profiling of follicular and papillary thyroid tumors. Eur J Endocrinol. 2012;166(4):657-667. doi: https://doi.org/10.1530/EJE-11-0856Wen J, Qin X, Zhang J, et al. Clinical significance of matrix metalloproteinase-9 expression in papillary thyroid carcinoma: a meta-analysis. World J Surg Oncol. 2023. doi: https://doi.org/10.1186/s12957-023-03101-xWen J, Qin X, Zhang J, et al. Clinical significance of matrix metalloproteinase-9 expression in papillary thyroid carcinoma: a meta-analysis. World J Surg Oncol. 2023. doi: https://doi.org/10.1186/s12957-023-03101-xGuan H, Guo Y, Liu L, et al. INAVA promotes aggressiveness of papillary thyroid cancer by upregulating MMP9 expression. Cell Biosci. 2018;8(1):26. doi: https://doi.org/10.1186/s13578-018-0224-4Guan H, Guo Y, Liu L, et al. INAVA promotes aggressiveness of papillary thyroid cancer by upregulating MMP9 expression. Cell Biosci. 2018;8(1):26. doi: https://doi.org/10.1186/s13578-018-0224-4Marečko I, Cvejić D, Šelemetjev S, et al. Enhanced activation of matrix metalloproteinase-9 correlates with the degree of papillary thyroid carcinoma infiltration. Croat Med J. 2014. doi: https://doi.org/10.3325/cmj.2014.55.128Marečko I, Cvejić D, Šelemetjev S, et al. Enhanced activation of matrix metalloproteinase-9 correlates with the degree of papillary thyroid carcinoma infiltration. Croat Med J. 2014. doi: https://doi.org/10.3325/cmj.2014.55.128Shi Y, Su C, Hu H, et al. Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma. Ahmad A, ed. PLoS One. 2018;13(6):e0198896. doi: https://doi.org/10.1371/journal.pone.0198896Shi Y, Su C, Hu H, et al. Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma. Ahmad A, ed. PLoS One. 2018;13(6):e0198896. doi: https://doi.org/10.1371/journal.pone.0198896Ali KM, Awny S, Ibrahim DA, et al. Role of P53, E-cadherin and BRAF as predictors of regional nodal recurrence for papillary thyroid cancer. Ann Diagn Pathol. 2019. doi: https://doi.org/10.1016/j.anndiagpath.2019.04.005Ali KM, Awny S, Ibrahim DA, et al. Role of P53, E-cadherin and BRAF as predictors of regional nodal recurrence for papillary thyroid cancer. Ann Diagn Pathol. 2019. doi: https://doi.org/10.1016/j.anndiagpath.2019.04.005Zhu X, Bai Q, Lu Y, et al. Expression and function of CXCL12/CXCR4/CXCR7 in thyroid cancer. Int J Oncol. 2016. doi: https://doi.org/10.3892/ijo.2016.3485Zhu X, Bai Q, Lu Y, et al. Expression and function of CXCL12/CXCR4/CXCR7 in thyroid cancer. Int J Oncol. 2016. doi: https://doi.org/10.3892/ijo.2016.3485Werner TA, Forster CM, Dizdar L, et al. CXCR4/CXCR7/CXCL12-Axis in follicular thyroid carcinoma. J Cancer. 2018. doi: https://doi.org/10.7150/jca.23042Werner TA, Forster CM, Dizdar L, et al. CXCR4/CXCR7/CXCL12-Axis in follicular thyroid carcinoma. J Cancer. 2018. doi: https://doi.org/10.7150/jca.23042Zhang W, Song B, Yang T. MMP-2, MMP-9, TIMP-1, and TIMP-2 in the Peripheral Blood of Patients with Differentiated Thyroid Carcinoma. Cancer Manag Res. 2019;Volume 11:10675-10681. doi: https://doi.org/10.2147/CMAR.S233776Zhang W, Song B, Yang T. MMP-2, MMP-9, TIMP-1, and TIMP-2 in the Peripheral Blood of Patients with Differentiated Thyroid Carcinoma. Cancer Manag Res. 2019;Volume 11:10675-10681. doi: https://doi.org/10.2147/CMAR.S233776Bumber B, Marjanovic Kavanagh M, Jakovcevic A, Sincic N, Prstacic R, Prgomet D. Role of matrix metalloproteinases and their inhibitors in the development of cervical metastases in papillary thyroid cancer. Clin Otolaryngol. 2020;45(1):55-62. doi: https://doi.org/10.1111/coa.13466Bumber B, Marjanovic Kavanagh M, Jakovcevic A, Sincic N, Prstacic R, Prgomet D. Role of matrix metalloproteinases and their inhibitors in the development of cervical metastases in papillary thyroid cancer. Clin Otolaryngol. 2020;45(1):55-62. doi: https://doi.org/10.1111/coa.13466Cho H, Kim J, Oh YL. Diagnostic value of HBME‐1, CK19, Galectin 3, and CD56 in the subtypes of follicular variant of papillary thyroid carcinoma. Pathol Int. 2018;68(11):605-613. doi: https://doi.org/10.1111/pin.12729Cho H, Kim J, Oh YL. Diagnostic value of HBME‐1, CK19, Galectin 3, and CD56 in the subtypes of follicular variant of papillary thyroid carcinoma. Pathol Int. 2018;68(11):605-613. doi: https://doi.org/10.1111/pin.12729Xin Y, Guan D, Meng K, Lv Z, Chen B. Diagnostic accuracy of CK-19, Galectin-3 and HBME-1 on papillary thyroid carcinoma: A meta-analysis. Int J Clin Exp Pathol. 2017. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965469/Xin Y, Guan D, Meng K, Lv Z, Chen B. Diagnostic accuracy of CK-19, Galectin-3 and HBME-1 on papillary thyroid carcinoma: A meta-analysis. Int J Clin Exp Pathol. 2017. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965469/Arcolia V, Journe F, Renaud F, et al. Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer. Oncol Lett. 2017. doi: https://doi.org/10.3892/ol.2017.6719Arcolia V, Journe F, Renaud F, et al. Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer. Oncol Lett. 2017. doi: https://doi.org/10.3892/ol.2017.6719Palo S, Biligi DS. Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions. Malays J Pathol. 2017.Palo S, Biligi DS. Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions. Malays J Pathol. 2017.Muthusamy S, Azhar Shah S, Abdullah Suhaimi SN, et al. CD56 expression in benign and malignant thyroid lesions. Malays J Pathol. 2018.Muthusamy S, Azhar Shah S, Abdullah Suhaimi SN, et al. CD56 expression in benign and malignant thyroid lesions. Malays J Pathol. 2018.Erdogan-Durmus S, Ozcan D, Yarikkaya E, Kurt A, Arslan A. CD56, HBME-1 and cytokeratin 19 expressions in papillary thyroid carcinoma and nodular thyroid lesions. J Res Med Sci. 2016. doi: https://doi.org/10.4103/1735-1995.183986Erdogan-Durmus S, Ozcan D, Yarikkaya E, Kurt A, Arslan A. CD56, HBME-1 and cytokeratin 19 expressions in papillary thyroid carcinoma and nodular thyroid lesions. J Res Med Sci. 2016. doi: https://doi.org/10.4103/1735-1995.183986Bartolazzi A, Sciacchitano S, D’Alessandria C. Galectin-3: The Impact on the Clinical Management of Patients with Thyroid Nodules and Future Perspectives. Int J Mol Sci. 2018;19(2):445. doi: https://doi.org/10.3390/ijms19020445Bartolazzi A, Sciacchitano S, D’Alessandria C. Galectin-3: The Impact on the Clinical Management of Patients with Thyroid Nodules and Future Perspectives. Int J Mol Sci. 2018;19(2):445. doi: https://doi.org/10.3390/ijms19020445Li J, Vasilyeva E, Wiseman SM. Beyond immunohistochemistry and immunocytochemistry: a current perspective on galectin-3 and thyroid cancer. Expert Rev Anticancer Ther. 2019;19(12):1017-1027. doi: https://doi.org/10.1080/14737140.2019.1693270Li J, Vasilyeva E, Wiseman SM. Beyond immunohistochemistry and immunocytochemistry: a current perspective on galectin-3 and thyroid cancer. Expert Rev Anticancer Ther. 2019;19(12):1017-1027. doi: https://doi.org/10.1080/14737140.2019.1693270Wang C-A, Tsai S-J. The non-canonical role of vascular endothelial growth factor-C axis in cancer progression. Exp Biol Med. 2015;240(6):718-724. doi: https://doi.org/10.1177/1535370215583802Wang C-A, Tsai S-J. The non-canonical role of vascular endothelial growth factor-C axis in cancer progression. Exp Biol Med. 2015;240(6):718-724. doi: https://doi.org/10.1177/1535370215583802Šelemetjev S, Đorić I, Paunović I, Tatić S, Cvejić D. Coexpressed High Levels of VEGF-C and Active MMP-9 Are Associated With Lymphatic Spreading and Local Invasiveness of Papillary Thyroid Carcinoma. Am J Clin Pathol. 2016;146(5):594-602. doi: https://doi.org/10.1093/ajcp/aqw184Šelemetjev S, Đorić I, Paunović I, Tatić S, Cvejić D. Coexpressed High Levels of VEGF-C and Active MMP-9 Are Associated With Lymphatic Spreading and Local Invasiveness of Papillary Thyroid Carcinoma. Am J Clin Pathol. 2016;146(5):594-602. doi: https://doi.org/10.1093/ajcp/aqw184Jang JY, Kim DS, Park HY, et al. Preoperative serum VEGF-C but not VEGF-A level is correlated with lateral neck metastasis in papillary thyroid carcinoma. Head Neck. 2019. doi: https://doi.org/10.1002/hed.25729Jang JY, Kim DS, Park HY, et al. Preoperative serum VEGF-C but not VEGF-A level is correlated with lateral neck metastasis in papillary thyroid carcinoma. Head Neck. 2019. doi: https://doi.org/10.1002/hed.25729Jia ZY, Wu XL, Zhang YH, Ma BL, Ma FC. The correlation between ultrasonographic features, bFGF, and the local invasiveness of thyroid papillary carcinoma. Med (United States). 2020. doi: https://doi.org/10.1097/MD.0000000000020644Jia ZY, Wu XL, Zhang YH, Ma BL, Ma FC. The correlation between ultrasonographic features, bFGF, and the local invasiveness of thyroid papillary carcinoma. Med (United States). 2020. doi: https://doi.org/10.1097/MD.0000000000020644Kitahara CM, Schneider AB. Epidemiology of Thyroid Cancer. Cancer Epidemiol Biomarkers Prev. 2022;31(7):1284-1297. doi: https://doi.org/10.1158/1055-9965.EPI-21-1440Kitahara CM, Schneider AB. Epidemiology of Thyroid Cancer. Cancer Epidemiol Biomarkers Prev. 2022;31(7):1284-1297. doi: https://doi.org/10.1158/1055-9965.EPI-21-1440Abdullah MI, Lee CC, Mat Junit S, Ng KL, Hashim OH. Tissue and serum samples of patients with papillary thyroid cancer with and without benign background demonstrate different altered expression of proteins. PeerJ. 2016;4:e2450. doi: https://doi.org/10.7717/peerj.2450Abdullah MI, Lee CC, Mat Junit S, Ng KL, Hashim OH. Tissue and serum samples of patients with papillary thyroid cancer with and without benign background demonstrate different altered expression of proteins. PeerJ. 2016;4:e2450. doi: https://doi.org/10.7717/peerj.2450Wei W, Wu Y, Chen DD, et al. Proteomics profiling for the global and acetylated proteins of papillary thyroid cancers. Proteome Sci. 2023. doi: https://doi.org/10.1186/s12953-023-00207-8Wei W, Wu Y, Chen DD, et al. Proteomics profiling for the global and acetylated proteins of papillary thyroid cancers. Proteome Sci. 2023. doi: https://doi.org/10.1186/s12953-023-00207-8Cheng S, Lee J, Chang Y, Lin C, Li Y, Liu C. Overexpression of chitinase‐3‐like protein 1 is associated with structural recurrence in patients with differentiated thyroid cancer. J Pathol. 2020;252(2):114-124. doi: https://doi.org/10.1002/path.5503Cheng S, Lee J, Chang Y, Lin C, Li Y, Liu C. Overexpression of chitinase‐3‐like protein 1 is associated with structural recurrence in patients with differentiated thyroid cancer. J Pathol. 2020;252(2):114-124. doi: https://doi.org/10.1002/path.5503Sponziello M, Rosignolo F, Celano M, et al. Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells. Mol Cell Endocrinol. 2016;431:123-132. doi: https://doi.org/10.1016/j.mce.2016.05.007Sponziello M, Rosignolo F, Celano M, et al. Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells. Mol Cell Endocrinol. 2016;431:123-132. doi: https://doi.org/10.1016/j.mce.2016.05.007Kang YE, Kim JM, Lim MA, et al. Growth Differentiation Factor 15 is a Cancer Cell-Induced Mitokine That Primes Thyroid Cancer Cells for Invasiveness. Thyroid. 2021. doi: https://doi.org/10.1089/thy.2020.0034Kang YE, Kim JM, Lim MA, et al. Growth Differentiation Factor 15 is a Cancer Cell-Induced Mitokine That Primes Thyroid Cancer Cells for Invasiveness. Thyroid. 2021. doi: https://doi.org/10.1089/thy.2020.0034Stępień T, Brożyna M, Kuzdak K, et al. Elevated Concentrations of SERPINE2/Protease Nexin-1 and Secretory Leukocyte Protease Inhibitor in the Serum of Patients with Papillary Thyroid Cancer. Dis Markers. 2017;2017:1-5. doi: https://doi.org/10.1155/2017/4962137Stępień T, Brożyna M, Kuzdak K, et al. Elevated Concentrations of SERPINE2/Protease Nexin-1 and Secretory Leukocyte Protease Inhibitor in the Serum of Patients with Papillary Thyroid Cancer. Dis Markers. 2017;2017:1-5. doi: https://doi.org/10.1155/2017/4962137Zhang W, Song B, Yang T. MMP-2, MMP-9, TIMP-1, and TIMP-2 in the Peripheral Blood of Patients with Differentiated Thyroid Carcinoma. Cancer Manag Res. 2019;Volume 11:10675-10681. doi: https://doi.org/10.2147/CMAR.S233776Zhang W, Song B, Yang T. MMP-2, MMP-9, TIMP-1, and TIMP-2 in the Peripheral Blood of Patients with Differentiated Thyroid Carcinoma. Cancer Manag Res. 2019;Volume 11:10675-10681. doi: https://doi.org/10.2147/CMAR.S233776Ye G, Zhang X, Li M, et al. Integrated analysis of circulating and tissue proteomes reveals that fibronectin 1 is a potential biomarker in papillary thyroid cancer. BMC Cancer. 2023;23(1):412. doi: https://doi.org/10.1186/s12885-023-10839-wYe G, Zhang X, Li M, et al. Integrated analysis of circulating and tissue proteomes reveals that fibronectin 1 is a potential biomarker in papillary thyroid cancer. BMC Cancer. 2023;23(1):412. doi: https://doi.org/10.1186/s12885-023-10839-wLu ZL, Chen YJ, Jing XY, Wang NN, Zhang T, Hu CJ. Detection and identification of serum peptides biomarker in papillary thyroid cancer. Med Sci Monit. 2018. doi: https://doi.org/10.12659/MSM.907768Lu ZL, Chen YJ, Jing XY, Wang NN, Zhang T, Hu CJ. Detection and identification of serum peptides biomarker in papillary thyroid cancer. Med Sci Monit. 2018. doi: https://doi.org/10.12659/MSM.907768Li D, Wu J, Liu Z, Qiu L, Zhang Y. Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry. PeerJ. 2020;8:e9507. doi: https://doi.org/10.7717/peerj.9507Li D, Wu J, Liu Z, Qiu L, Zhang Y. Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry. PeerJ. 2020;8:e9507. doi: https://doi.org/10.7717/peerj.9507Hannan JP, Laskowski J, Thurman JM, Hageman GS, Holers VM. Mapping the Complement Factor H-Related Protein 1 (CFHR1):C3b/C3d Interactions. Rooijakkers SH, ed. PLoS One. 2016;11(11):e0166200. doi: https://doi.org/10.1371/journal.pone.0166200Hannan JP, Laskowski J, Thurman JM, Hageman GS, Holers VM. Mapping the Complement Factor H-Related Protein 1 (CFHR1):C3b/C3d Interactions. Rooijakkers SH, ed. PLoS One. 2016;11(11):e0166200. doi: https://doi.org/10.1371/journal.pone.0166200Farrokhi Yekta R, Arefi Oskouie A, Rezaei Tavirani M, Mohajeri-Tehrani MR, Soroush AR. Decreased apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid carcinoma: A proteomic study. Int J Biol Markers. 2018;33(4):455-462. doi: https://doi.org/10.1177/1724600818787752Farrokhi Yekta R, Arefi Oskouie A, Rezaei Tavirani M, Mohajeri-Tehrani MR, Soroush AR. Decreased apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid carcinoma: A proteomic study. Int J Biol Markers. 2018;33(4):455-462. doi: https://doi.org/10.1177/1724600818787752Hu Z, Zhao P, Zhang K, Zang L, Liao H, Ma W. Evaluation of Serum Vascular Adhesion Protein-1 as a Potential Biomarker in Thyroid Cancer. Int J Endocrinol. 2016;2016:1-7. doi: https://doi.org/10.1155/2016/6312529Hu Z, Zhao P, Zhang K, Zang L, Liao H, Ma W. Evaluation of Serum Vascular Adhesion Protein-1 as a Potential Biomarker in Thyroid Cancer. Int J Endocrinol. 2016;2016:1-7. doi: https://doi.org/10.1155/2016/6312529Baki A, Tosun İ, Yıldız M. Can VAP-1 Protein be used as a Biomarker in Thyroid Cancer? İstanbul Med J. 2019;20(6):535-540. doi: https://doi.org/10.4274/imj.galenos.2019.26817Baki A, Tosun İ, Yıldız M. Can VAP-1 Protein be used as a Biomarker in Thyroid Cancer? İstanbul Med J. 2019;20(6):535-540. doi: https://doi.org/10.4274/imj.galenos.2019.26817Colombo M, Raposo G, Théry C. Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles. Annu Rev Cell Dev Biol. 2014;30(1):255-289. doi: https://doi.org/10.1146/annurev-cellbio-101512-122326Colombo M, Raposo G, Théry C. Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles. Annu Rev Cell Dev Biol. 2014;30(1):255-289. doi: https://doi.org/10.1146/annurev-cellbio-101512-122326Luo D, Zhan S, Xia W, Huang L, Ge W, Wang T. Proteomics study of serum exosomes from papillary thyroid cancer patients. Endocr Relat Cancer. 2018;25(10):879-891. doi: https://doi.org/10.1530/ERC-17-0547Luo D, Zhan S, Xia W, Huang L, Ge W, Wang T. Proteomics study of serum exosomes from papillary thyroid cancer patients. Endocr Relat Cancer. 2018;25(10):879-891. doi: https://doi.org/10.1530/ERC-17-0547Henderson YC, Toro–Serra R, Chen Y, et al. Src inhibitors in suppression of papillary thyroid carcinoma growth. Head Neck. 2014;36(3):375-384. doi: https://doi.org/10.1002/hed.23316Henderson YC, Toro–Serra R, Chen Y, et al. Src inhibitors in suppression of papillary thyroid carcinoma growth. Head Neck. 2014;36(3):375-384. doi: https://doi.org/10.1002/hed.23316Lai X, Umbricht CB, Fisher K, Bishop J, Shi Q, Chen S. Identification of novel biomarker and therapeutic target candidates for diagnosis and treatment of follicular carcinoma. J Proteomics. 2017. doi: https://doi.org/10.1016/j.jprot.2017.07.003Lai X, Umbricht CB, Fisher K, Bishop J, Shi Q, Chen S. Identification of novel biomarker and therapeutic target candidates for diagnosis and treatment of follicular carcinoma. J Proteomics. 2017. doi: https://doi.org/10.1016/j.jprot.2017.07.003Huang D, Zhang H, Li L, et al. Proteotypic Differences of Follicular-Patterned Thyroid Neoplasms. Front Endocrinol (Lausanne). 2022. doi: https://doi.org/10.3389/fendo.2022.854611Huang D, Zhang H, Li L, et al. Proteotypic Differences of Follicular-Patterned Thyroid Neoplasms. Front Endocrinol (Lausanne). 2022. doi: https://doi.org/10.3389/fendo.2022.854611Ucal Y, Tokat F, Duren M, Ince U, Ozpinar A. Peptide Profile Differences of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features, Encapsulated Follicular Variant, and Classical Papillary Thyroid Carcinoma: An Application of Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging. Thyroid. 2019. doi: https://doi.org/10.1089/thy.2018.0392Ucal Y, Tokat F, Duren M, Ince U, Ozpinar A. Peptide Profile Differences of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features, Encapsulated Follicular Variant, and Classical Papillary Thyroid Carcinoma: An Application of Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging. Thyroid. 2019. doi: https://doi.org/10.1089/thy.2018.0392Belousov P V., Bogolyubova A V., Kim YS, et al. Serum immunoproteomics combined with pathological reassessment of surgical specimens identifies TCP-1ζ autoantibody as a potential biomarker in thyroid neoplasia. J Clin Endocrinol Metab. 2015. doi: https://doi.org/10.1210/jc.2014-4260Belousov P V., Bogolyubova A V., Kim YS, et al. Serum immunoproteomics combined with pathological reassessment of surgical specimens identifies TCP-1ζ autoantibody as a potential biomarker in thyroid neoplasia. J Clin Endocrinol Metab. 2015. doi: https://doi.org/10.1210/jc.2014-4260Zhu QL, Wang TF, Cao QIF, Zheng MH, Lu AG. Inhibition of cytosolic chaperonin CCTζ-1 expression depletes proliferation of colorectal carcinoma in vitro. J Surg Oncol. 2010. doi: https://doi.org/10.1002/jso.21625Zhu QL, Wang TF, Cao QIF, Zheng MH, Lu AG. Inhibition of cytosolic chaperonin CCTζ-1 expression depletes proliferation of colorectal carcinoma in vitro. J Surg Oncol. 2010. doi: https://doi.org/10.1002/jso.21625Lanshchakov K V, Belousov P V, Vanushko VE, Abrosimov AY, Kuprash D V, Kuznetsov NS. Autoantibody profiling of benign and malignant thyroid tumors and design of a prototype diagnostic array. Endocr Surg. 2012;(2):15. doi: https://doi.org/10.14341/2306-3513-2012-2-15-20Lanshchakov K V, Belousov P V, Vanushko VE, Abrosimov AY, Kuprash D V, Kuznetsov NS. Autoantibody profiling of benign and malignant thyroid tumors and design of a prototype diagnostic array. Endocr Surg. 2012;(2):15. doi: https://doi.org/10.14341/2306-3513-2012-2-15-20Lu H, Pan Y, Ruan Y, et al. Biomarker Discovery for Early Diagnosis of Papillary Thyroid Carcinoma Using High-Throughput Enhanced Quantitative Plasma Proteomics. J Proteome Res. 2023. doi: https://doi.org/10.1021/acs.jproteome.3c00187Lu H, Pan Y, Ruan Y, et al. Biomarker Discovery for Early Diagnosis of Papillary Thyroid Carcinoma Using High-Throughput Enhanced Quantitative Plasma Proteomics. J Proteome Res. 2023. doi: https://doi.org/10.1021/acs.jproteome.3c00187Sofiadis A, Dinets A, Orre LM, et al. Proteomic Study of Thyroid Tumors Reveals Frequent Up-Regulation of the Ca 2+ -Binding Protein S100A6 in Papillary Thyroid Carcinoma. Thyroid. 2010;20(10):1067-1076. doi: https://doi.org/10.1089/thy.2009.0400Sofiadis A, Dinets A, Orre LM, et al. Proteomic Study of Thyroid Tumors Reveals Frequent Up-Regulation of the Ca 2+ -Binding Protein S100A6 in Papillary Thyroid Carcinoma. Thyroid. 2010;20(10):1067-1076. doi: https://doi.org/10.1089/thy.2009.0400Li D, Wu J, Liu Z, Qiu L, Zhang Y. Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry. PeerJ. 2020;8:e9507. doi: https://doi.org/10.7717/peerj.9507Li D, Wu J, Liu Z, Qiu L, Zhang Y. Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry. PeerJ. 2020;8:e9507. doi: https://doi.org/10.7717/peerj.9507Shirazkeytabar K, Razavi SA, Abooshahab R, et al. Elevated Plasma Levels of MT4-MMP and MT6-MMP; A New Observation in Patients with Thyroid Nodules. Arch Iran Med. 2023;26(6):338-345. doi: https://doi.org/10.34172/aim.2023.51Shirazkeytabar K, Razavi SA, Abooshahab R, et al. Elevated Plasma Levels of MT4-MMP and MT6-MMP; A New Observation in Patients with Thyroid Nodules. Arch Iran Med. 2023;26(6):338-345. doi: https://doi.org/10.34172/aim.2023.51Sun Z, Feng D, Jiang L, Tian J, Wang J, Zhu W. Integrated proteomic and metabolomic analysis of plasma reveals regulatory pathways and key elements in thyroid cancer. Mol Omi. 2023. doi: https://doi.org/10.1039/d3mo00142cSun Z, Feng D, Jiang L, Tian J, Wang J, Zhu W. Integrated proteomic and metabolomic analysis of plasma reveals regulatory pathways and key elements in thyroid cancer. Mol Omi. 2023. doi: https://doi.org/10.1039/d3mo00142cBrown LM, Helmke SM, Hunsucker SW, et al. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog. 2006;45(8):613-626. doi: https://doi.org/10.1002/mc.20193Brown LM, Helmke SM, Hunsucker SW, et al. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog. 2006;45(8):613-626. doi: https://doi.org/10.1002/mc.20193Abdullah MI, Lee CC, Mat Junit S, Ng KL, Hashim OH. Tissue and serum samples of patients with papillary thyroid cancer with and without benign background demonstrate different altered expression of proteins. PeerJ. 2016;4:e2450. doi: https://doi.org/10.7717/peerj.2450Abdullah MI, Lee CC, Mat Junit S, Ng KL, Hashim OH. Tissue and serum samples of patients with papillary thyroid cancer with and without benign background demonstrate different altered expression of proteins. PeerJ. 2016;4:e2450. doi: https://doi.org/10.7717/peerj.2450Martínez-Aguilar J, Clifton-Bligh R, Molloy MP. Proteomics of thyroid tumours provides new insights into their molecular composition and changes associated with malignancy. Sci Rep. 2016. doi: https://doi.org/10.1038/srep23660Martínez-Aguilar J, Clifton-Bligh R, Molloy MP. Proteomics of thyroid tumours provides new insights into their molecular composition and changes associated with malignancy. Sci Rep. 2016. doi: https://doi.org/10.1038/srep23660Detection of cathepsin B up‐regulation in neoplastic thyroid tissues by proteomic analysis — Srisomsap — 2002 — PROTEOMICS — Wiley Online Library. Accessed: 2024. [Online]. Available: https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/1615-9861(200206)2:6%3C706::AID-PROT706%3E3.0.CO;2-EDetection of cathepsin B up‐regulation in neoplastic thyroid tissues by proteomic analysis — Srisomsap — 2002 — PROTEOMICS — Wiley Online Library. Accessed: 2024. [Online]. Available: https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/1615-9861(200206)2:6%3C706::AID-PROT706%3E3.0.CO;2-ESofiadis A, Becker S, Hellman U, et al. Proteomic profiling of follicular and papillary thyroid tumors. Eur J Endocrinol. 2012;166(4):657-667. doi: https://doi.org/10.1530/EJE-11-0856Sofiadis A, Becker S, Hellman U, et al. Proteomic profiling of follicular and papillary thyroid tumors. Eur J Endocrinol. 2012;166(4):657-667. doi: https://doi.org/10.1530/EJE-11-0856Ucal Y, Tokat F, Duren M, Ince U, Ozpinar A. Peptide Profile Differences of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features, Encapsulated Follicular Variant, and Classical Papillary Thyroid Carcinoma: An Application of Matrix-Assisted Laser Desorption/Ionization Mass Spe. Thyroid. 2019;29(8):1125-1137. doi: https://doi.org/10.1089/thy.2018.0392Ucal Y, Tokat F, Duren M, Ince U, Ozpinar A. Peptide Profile Differences of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features, Encapsulated Follicular Variant, and Classical Papillary Thyroid Carcinoma: An Application of Matrix-Assisted Laser Desorption/Ionization Mass Spe. Thyroid. 2019;29(8):1125-1137. doi: https://doi.org/10.1089/thy.2018.0392Ucal Y, Eravci M, Tokat F, Duren M, Ince U, Ozpinar A. Proteomic analysis reveals differential protein expression in variants of papillary thyroid carcinoma. EuPA Open Proteomics. 2017;17:1-6. doi: https://doi.org/10.1016/j.euprot.2017.09.001Ucal Y, Eravci M, Tokat F, Duren M, Ince U, Ozpinar A. Proteomic analysis reveals differential protein expression in variants of papillary thyroid carcinoma. EuPA Open Proteomics. 2017;17:1-6. doi: https://doi.org/10.1016/j.euprot.2017.09.001Luo D, Zhan S, Xia W, Huang L, Ge W, Wang T. Proteomics study of serum exosomes from papillary thyroid cancer patients. Endocr Relat Cancer. 2018;25(10):879-891. doi: https://doi.org/10.1530/ERC-17-0547Luo D, Zhan S, Xia W, Huang L, Ge W, Wang T. Proteomics study of serum exosomes from papillary thyroid cancer patients. Endocr Relat Cancer. 2018;25(10):879-891. doi: https://doi.org/10.1530/ERC-17-0547Трошина Е.А., Юшков П.В., Абесадзе И.А., Орджоникидзе М.К. Клинические, морфологические и иммуногистохимические особенности фолликулярных опухолей щитовидной железы результаты ретроспективного исследования // II научная конференция Клиническая 30 морфология новообразований эндокринных желез. Москва. — 2007. — С. 153.Трошина Е.А., Юшков П.В., Абесадзе И.А., Орджоникидзе М.К. Клинические, морфологические и иммуногистохимические особенности фолликулярных опухолей щитовидной железы результаты ретроспективного исследования // II научная конференция Клиническая 30 морфология новообразований эндокринных желез. Москва. — 2007. — С. 153.

The authors declare that there are no conflicts of interest present.